Controversies in NSCLC: which second-line strategy after chemo-immunotherapy?

ABSTRACT:

SUBMITTER: Moliner L 

PROVIDER: S-EPMC9958277 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature